TY - JOUR
T1 - Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people
AU - Sullivan, Shelby
AU - Fabbrini, Elisa
AU - Horton, Jay D.
AU - Korenblat, Kevin
AU - Patterson, Bruce W.
AU - Klein, Samuel
N1 - Funding Information:
Supported by grants DK 37948, DK 56341 ( Nutrition and Obesity Research Center ), HL 20948, and UL1RR024992/ KL2RR024994 from the National Institutes of Health, an AGA Roche Junior Faculty Clinical Research Award in Hepatology and the Robert and Veronica Atkins Foundation .
PY - 2011/11
Y1 - 2011/11
N2 - Obesity is associated with unfavorable alterations in plasma lipid concentrations. Data obtained from studies in cultured cells and rodent models show that Protein Convertase Subtilisn/Kexin 9 (PCSK9), a secreted protein that leads to degradation of LDL receptors in the liver, is an important regulator of plasma LDL cholesterol concentrations. Recent evidence suggests that PCSK9 may also regulate the very low density lipoprotein (VLDL) receptor expression and VLDL-triglyceride (TG) metabolism. The purpose of this study was to determine whether circulating PCSK9 concentrations are correlated with VLDL-triglyceride kinetics in obese people. Plasma PCSK9 concentration and VLDL-TG kinetics were evaluated in 39 nondiabetic, obese subjects (body mass index 36.9 ± 4.3 kg/m2). Body composition was assessed by using dual-energy x-ray absorptiometry, and VLDL-TG kinetics were assessed by using stable isotopically labeled tracer infusion. We found that plasma PCSK9 concentrations correlated significantly with percent body fat (r = 0.322, P = 0.046) and serum LDL-cholesterol concentrations (r = 0.333, P = 0.036), but not with VLDL-TG secretion rate (r = 0.083, P = 0.614) or clearance rate (r = 0.032, P = 0.845). These data suggest that PCSK9 is likely involved in LDL-cholesterol metabolism, but it is not a clinically important regulator of VLDL kinetics in obese individuals.
AB - Obesity is associated with unfavorable alterations in plasma lipid concentrations. Data obtained from studies in cultured cells and rodent models show that Protein Convertase Subtilisn/Kexin 9 (PCSK9), a secreted protein that leads to degradation of LDL receptors in the liver, is an important regulator of plasma LDL cholesterol concentrations. Recent evidence suggests that PCSK9 may also regulate the very low density lipoprotein (VLDL) receptor expression and VLDL-triglyceride (TG) metabolism. The purpose of this study was to determine whether circulating PCSK9 concentrations are correlated with VLDL-triglyceride kinetics in obese people. Plasma PCSK9 concentration and VLDL-TG kinetics were evaluated in 39 nondiabetic, obese subjects (body mass index 36.9 ± 4.3 kg/m2). Body composition was assessed by using dual-energy x-ray absorptiometry, and VLDL-TG kinetics were assessed by using stable isotopically labeled tracer infusion. We found that plasma PCSK9 concentrations correlated significantly with percent body fat (r = 0.322, P = 0.046) and serum LDL-cholesterol concentrations (r = 0.333, P = 0.036), but not with VLDL-TG secretion rate (r = 0.083, P = 0.614) or clearance rate (r = 0.032, P = 0.845). These data suggest that PCSK9 is likely involved in LDL-cholesterol metabolism, but it is not a clinically important regulator of VLDL kinetics in obese individuals.
UR - http://www.scopus.com/inward/record.url?scp=80054696614&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054696614&partnerID=8YFLogxK
U2 - 10.1016/j.trsl.2011.06.006
DO - 10.1016/j.trsl.2011.06.006
M3 - Article
C2 - 22005270
AN - SCOPUS:80054696614
SN - 1931-5244
VL - 158
SP - 302
EP - 306
JO - Translational Research
JF - Translational Research
IS - 5
ER -